RIPK1 and amyotrophic lateral sclerosis: Further evidence that necroptosis may be involved in ALS neurodegeneration comes from in vivo studies in which the administration of the small molecule Nec-1s, a kinase antagonist of the receptor-interacting protein kinase 1 (RIPK1), or deletion of RIPK3, two key determinants of necroptosis (Grootjans et al., 2017), was shown to delay the onset of the ALS phenotype in Tg SOD1G93A mice (Ito et al., 2016).